StockData
Gain Therapeutics, Inc. logo

Gain Therapeutics, Inc. (GANX) stock

GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/30
$1.18+0.24 (+25.51%)

Close on Nov 17, 2026Market cap $51.50MP/E –Yield –

Gain Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Gain Therapeutics's total debt was $343.69K at Jun 30, 2026. For fiscal 2025 it was $400.95K, down 8.6% from the year before. The highest annual figure on record is $738.28K in fiscal 2020.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$400.95K-8.6%
FY2024Dec 31, 2024$438.50K-22.8%
FY2023Dec 31, 2023$567.85K-5.9%
FY2022Dec 31, 2022$603.39K-13.1%
FY2021Dec 31, 2021$694.29K-6.0%
FY2020Dec 31, 2020$738.28K–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$343.69K-23.9%
Q1 FY2026Mar 31, 2026$373.55K-12.6%
Q4 FY2025Dec 31, 2025$400.95K-8.6%
Q3 FY2025Sep 30, 2025$424.34K-14.2%
Q2 FY2025Jun 30, 2025$451.47K-7.2%
Q1 FY2025Mar 31, 2025$427.60K-15.8%
Q4 FY2024Dec 31, 2024$438.50K-22.8%
Q3 FY2024Sep 30, 2024$494.41K-9.2%
Q2 FY2024Jun 30, 2024$486.40K-15.9%
Q1 FY2024Mar 31, 2024$507.68K-13.6%
Q4 FY2023Dec 31, 2023$567.85K-5.9%
Q3 FY2023Sep 30, 2023$544.22K-7.0%
Q2 FY2023Jun 30, 2023$578.27K-7.6%
Q1 FY2023Mar 31, 2023$587.50K-9.3%
Q4 FY2022Dec 31, 2022$603.39K-13.1%
Q3 FY2022Sep 30, 2022$585.28K-17.2%
Q2 FY2022Jun 30, 2022$626.01K-12.1%
Q1 FY2022Mar 31, 2022$647.51K-10.4%
Q4 FY2021Dec 31, 2021$694.29K-6.0%
Q3 FY2021Sep 30, 2021$706.81K–
Q2 FY2021Jun 30, 2021$712.14K–
Q1 FY2021Mar 31, 2021$722.54K–
Q4 FY2020Dec 31, 2020$738.28K–

More Gain Therapeutics figures

See a number that looks wrong?